Research article

Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison

Asma Sultana¹, Paula Ghaneh¹, David Cunningham², Naureen Starling², John P Neoptolemos¹ and Catrin Tudur Smith*¹,³

Address: ¹CRUK Liverpool Cancer Trials Unit, Cancer Research Centre, 200 London Road, Liverpool, L3 9TA, UK, ²Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK and ³Centre for Medical Statistics and Health Evaluation, University of Liverpool, Shelley’s Cottage, Brownlow Street, Liverpool, L69 3GS, UK

Email: Asma Sultana - asmasul@liv.ac.uk; Paula Ghaneh - P.Ghaneh@liverpool.ac.uk; David Cunningham - David.Cunningham@rmh.nhs.uk; Naureen Starling - Naureen.Starling@icr.ac.uk; John P Neoptolemos - j.p.neoptolemos@liv.ac.uk; Catrin Tudur Smith* - cat1@liverpool.ac.uk

* Corresponding author

Abstract

Background: Recent meta-analyses have found a survival advantage with gemcitabine based combinations over single agent gemcitabine in patients with advanced pancreatic cancer. There is paucity of evidence in the form of direct head-to-head randomised controlled trials to determine which combinations are to be preferred.

Method: Using the adjusted indirect comparison method proposed by Bucher et al, we have assessed randomised controlled trials of four gemcitabine based combinations namely gemcitabine plus a platinum compound or 5-fluorouracil or irinotecan or capecitabine.

Results: No particular combination was significantly superior to another, but the indirect evidence suggests some important trends.

Conclusion: The strongest trends on indirect comparison are towards favouring gemcitabine plus capecitabine or gemcitabine plus a platinum compound over gemcitabine plus irinotecan, and to a lesser degree, over gemcitabine plus 5-fluorouracil.

Background

We have previously reported a systematic review and meta-analysis of 19 studies evaluating gemcitabine based combination chemotherapy compared to gemcitabine alone [1] in patients with locally advanced and metastatic pancreatic cancer. Overall survival was significantly better for gemcitabine based combination chemotherapy (14 trials 4060 patients HR 0.91; 95% CI 0.85 to 0.97) compared to single agent gemcitabine. A subgroup analysis was performed, dividing the selected studies into four categories defined by the addition to gemcitabine of platinum agents or 5-fluorouracil (5FU) or irinotecan or capecitabine (Table 1). The subgroup analysis found evidence to suggest a survival advantage for gemcitabine combined with either a platinum agent (HR 0.85; 95% CI 0.74 to 0.96) or capecitabine (HR 0.83; 95% CI 0.72 to 0.96), and insufficient evidence to support combinations of gemcitabine with either 5FU (HR 0.98; 95% CI 0.86 to 1.11) or irinotecan (HR 1.01; 95% CI 0.84 to 1.22). These analyses provide estimates of the survival advantage for each combination compared to single agent gemcitabine but do not provide estimates of the survival advantage for
Table 1: List of included studies utilised in indirect comparison of gemcitabine based combination chemotherapy

| Comparison                                      | Trial                                                                 | Group (number randomised)               |
|------------------------------------------------|----------------------------------------------------------------------|-----------------------------------------|
| Gemcitabine versus gemcitabine plus capecitabine | Cunningham 2005 (interim analyses) [12]                            | Gemcitabine (n = 266)                  |
|                                                 | Hermann 2005 [13,14] (analyses based on data from abstract published in 2005, plus extra data provided by trialist) | Gemcitabine combination (n = 267)      |
|                                                 | Scheithauer 2003 [15]                                               | Gemcitabine (n = 159)                  |
|                                                 |                                                                     | Gemcitabine combination (n = 160)      |
| Gemcitabine versus gemcitabine plus 5FU         | Berlin 2002 [8]                                                    | Gemcitabine (n = 162)                  |
|                                                 | Di Costanzo 2005 [10]                                              | Gemcitabine combination (n = 160)      |
|                                                 | Reiss 2005 [9]                                                     | Gemcitabine (n = 48)                   |
| Gemcitabine versus gemcitabine plus platinum compound | Heinemann 2006 [16]                                                | Gemcitabine combination (n = 236)      |
|                                                 | Louvet 2005 [17]                                                   | Gemcitabine (n = 163)                  |
|                                                 | Poplin 2006 [18]                                                   | Gemcitabine combination (n = 163)      |
| Gemcitabine versus gemcitabine plus irinotecan  | Rocha Lima 2004 [19]                                               | Gemcitabine (n = 280)                  |
|                                                 | Stathopoulos 2005 [20,21] (analyses based on data from abstract published in 2005, plus extra data provided by trialist) | Gemcitabine combination (n = 276)      |

log HR\textsubscript{AB} = log HR\textsubscript{AC} - log HR\textsubscript{BC}

where log HR\textsubscript{AC} was the log hazard ratio for the direct comparison of intervention A versus C and log HR\textsubscript{BC} was the log hazard ratio for the direct comparison of intervention B versus C.

(2) The standard error for the log hazard ratio was obtained using the calculation:

SE (log HR\textsubscript{AB}) = \sqrt{SE (log HR\textsubscript{AC})^2 + SE (log HR\textsubscript{BC})^2}

where SE (log HR\textsubscript{AC}) was the standard error of the log hazard ratio for the direct comparison of intervention A versus C and SE (log HR\textsubscript{BC}) was the standard error of the log hazard ratio for the direct comparison of intervention B versus C.

The assumption of exchangeable treatment effects (treatment effect observed in trials comparing A versus C is assumed to be the treatment effect that would have been observed in those trials comparing B versus C if treatment A had been included in those trials and vice versa) across comparisons was evaluated by assessing heterogeneity across trials within each comparison and assessing comparability (methodological and clinical characteristics) of all trials contributing to the indirect comparison.
Results
Adjusted indirect comparisons were computed for the following comparisons:

1. Gemcitabine plus a platinum agent versus gemcitabine plus 5FU (GemPlat versus Gem5FU)
2. Gemcitabine plus a platinum agent versus gemcitabine plus capecitabine (GemPlat versus GemCap)
3. Gemcitabine plus a platinum agent versus gemcitabine plus irinotecan (GemPlat versus GemIrino)
4. Gemcitabine plus 5FU agent versus gemcitabine plus capecitabine (Gem5FU versus GemCap)
5. Gemcitabine plus 5FU agent versus gemcitabine plus irinotecan (Gem5FU versus GemIrino).
6. Gemcitabine plus capecitabine versus gemcitabine plus irinotecan (GemCap versus GemIrino).

We did not find any one combination to be significantly superior to others (Fig 1), but the indirect evidence suggests some important trends, of which the strongest are towards favouring gemcitabine plus capecitabine or gemcitabine plus a platinum compound over gemcitabine plus irinotecan (GemCap versus GemIrino HR 0.82, 95% CI 0.65 to 1.04; GemPlat versus GemIrino HR 0.84, 95% CI 0.67 to 1.06). Some advantage, to a lesser degree, was suggested for these two combinations over gemcitabine plus 5FU (Gem5FU versus GemCap HR 1.17, 95% CI 0.94 to 1.46; GemPlat versus Gem5FU HR 0.88, 95% CI 0.70 to 1.09). There was no evidence for heterogeneity within the direct comparisons and no obvious inconsistency with the assumption of exchangeable treatment effects.

Overall survival data was extracted from the single phase II randomised trial to allow estimation of a HR (95% CI) [5] for the direct comparison between GemOx and GemCap. There was no significant difference in overall survival between the two combinations (HR 0.81, 95% CI 0.56 to 1.18) on direct head-to-head comparison [2] as well as on computing this combining the results of both the direct and indirect comparisons (HR 0.94, 95% CI 0.79 to 1.12) using random effects analysis.

Discussion
In a situation wherein two drugs A and B have, in randomised controlled trials, shown to be effective in comparison to a placebo or common standard, but direct comparison between A and B is not available, indirect comparison can be used [4]. The use of a simple indirect comparison has the limitation that the difference detected may not be a true difference, but instead be attributable to variations in patient characteristics and other prognostic factors in the different trials. An adjusted indirect comparison method was proposed by Bucher et al, and this method maintains the randomisation of the originally assigned patients while calculating the magnitude of the treatment effect.

Song et al assessed the comparability of indirect with the direct head to head comparison in the setting of clinical
that capecitabine, an oral prodrug of 5FU, has the advantage of an element of tumour targeting, leading to enhanced selectivity and better tolerability [7]. The higher levels of thymidine phosphorylase (the final requisite enzyme for conversion of capecitabine to 5FU) observed in tumours compared to normal tissue may account for the improved targeting. Another possibility is the mode of delivery of 5FU versus capecitabine. The 5FU trials have involved bolus 5FU schedule [8] or 24 hour infusion [9], with the exception of one trial where 5FU was given by continuous infusion [10]. In contrast, the administration of capecitabine is more analogous to the delivery of 5FU by continuous protracted venous infusion, with the added ease of oral administration.

In the light of level I evidence demonstrating that gemcitabine based combinations have a modest survival advantage over single agent gemcitabine, the current study indicates which combinations may be more efficacious. The findings of our original meta-analyses, as well as the trends observed on our adjusted indirect comparisons support the use of gemcitabine in combination with either capecitabine or a platinum compound in clinical practice. Future randomised controlled trials will now likely to be centred on the exploitation of novel targets or biology (such as Telovac) [11] in this chemo-resistant cancer, probably on a cytotoxic backbone of a gemcitabine combination.

**Conclusion**

Adjusted indirect comparison of randomised controlled trials examining gemcitabine in combination with capecitabine, platinum based compounds, 5FU and irinotecan reveal trends towards favouring gemcitabine plus capecitabine or gemcitabine plus a platinum compound over gemcitabine plus irinotecan and to a lesser degree, over gemcitabine plus 5-fluorouracil. Future trials will now likely to be centred on the exploitation of novel targets or biology, probably on a cytotoxic backbone of a gemcitabine combination.

**Abbreviations**

CI: Confidence interval; GemCap: Gemcitabine plus capecitabine; GemIrino: Gemcitabine plus irinotecan; GemPlat: Gemcitabine plus platinum compound; HR: Hazard ratio.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

AS, CTS, JPN and PG were involved in the study design, data collection and analysis and manuscript write-up. DC and NS were involved in drafting the manuscript. All authors have read and approved the final manuscript.
Acknowledgements

Cancer Research UK

References

1. Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos J, Ghanekar P: Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer. J Clin Oncol 2007, 25(16):2212-7.

2. Roche Lima C, Green M, Rotche R, Miller W, Jeffrey G, Cisar L, Mortiari R, Alberts S, Bensa A: A randomized phase III trial of gemcitabine plus oxaliplatin in patients with advanced pancreatic cancer. J Clin Oncol 2009, 27:340-347.

3. Song F, Glenny A-M, Altman D: Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery. Control Clin Trials 2000, 21(5):488-497.

4. Boucher H, Guyatt G, Griffith L, Walter S: The results of direct and indirect treatment comparisons in meta-analysis of randomised controlled trials. J Clin Epidemiol 1997, 50(6):683-691.

5. Parmar M, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998, 17:2815-2834.

6. Song F, Altman D, Glenny A-N, Deeks J: Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003, 326(7387):472-477.

7. Smith DB, Neoptolemos JP: Capecitabine in carcinoma of the pancreas. Expert Opin Pharmacother 2006, 7(12):1633-1639.

8. Begg CB, Swerdlow, C. A randomised, prospective, multicentre, phase III trial of gemcitabine plus oxaliplatin versus gemcitabine monotherapy in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002, 20(15):3270-3275.

9. Pissis H, Helma A, Niedergermmann M, Schmid-Wolf I, Moek M, Hammer C, Zippel K, Weingang-Kohler K, Stauh M, Oettle H: A randomised, prospective, multicentre, phase III trial of gemcitabine, 5-Fluorouracil, folinic acid versus gemcitabine in patients with advanced pancreatic cancer. ASCO Annual Meeting 2003, abstract no. LBA4009.

10. Di Costanzo F, Carlini P, Doni L, Massidda B, Mattioli R, Iop A, Barletta E, Moscetti L, Recchia F, Tralongo P, Gasperoni S: Gemcitabine with or without continuous infusion S-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). Br J Cancer 2005, 93:185-189.

11. UK Clinical Research Network: TeloVac: A prospective, phase III, controlled, multicentre, randomised clinical trial comparing combination Gemcitabine and Cepacitabine therapy with concurrent and sequential chemoimmunotherapy using a telomerase vaccine in locally advanced and metastatic pancreatic cancer. 2007 [http://pssearch.ukcn.org.uk/StudyDetail.aspx?TopId=1&StudyId=2210].

12. Cunningham D, Chau I, Stocken D, Davies C, Dunn J, Valle J, Smith D, Steward W, Harper P, Neoptolemos J: Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Cancer 2005, 41: Abstract PS11.

13. Hermann R, Bodoky G, Ruhstaller T, Glimelius B, Saletti P, Bajetta E, Schueller J, Bernard H, Dietrich D, Scheithauer W: Gemcitabine plus capecitabine versus gemcitabine alone in locally advanced or metastatic pancreatic cancer. A randomised, phase III study of the Swtss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). 2005 ASCO Annual Meeting: 2005; Orlando, USA 2005. Abstract no. LBA4010.

14. Hermann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schueller J, Saletti P, Bauer J, Figar A, Festalozzi B, Kohne C, Miongione W, Stemmer S, Tamas K, Kornek GV, Kieblerle D, Cina S, Bernard H, Dietrich D, Scheithauer W, Swiss Group for Clinical Cancer Research, Central European Cooperative Oncology Group: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomised, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007, 25(16):2212-7.

15. Scheithauer W, Schull B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Kornek GV: Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomised phase II trial. Ann Oncol 2003, 14:97-104.

16. Heinemann V, Vizichis D, Gieseke F, Sonnermann M, Schonakers H, Rost A, Neuhau H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Geiserich W, Uthgennant D, Ensele H, Holstege A, Hinke A, Schalthorn A, Wilkowski R: Randomised phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006, 24(24):3946-3952.

17. Louvet C, Lablanca R, Hampel P, Lledo G, Zampino M, Andre T, Zaniboni A, Ducreux M, Attini E, Taieb J, Faroux R, Lepere C, de Gramont A: Gemcitabine in combination with oxaliplatin compared in colorectal cancer. BMC Cancer 2007, 7:245.

18. Poplin E, Levy D, Berlin J, Rothenberg M, Cells D, Mitchell E, Alberts S, Benson A: Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose rate infusion) versus gemcitabine + oxaliplatin in patients with advanced pancreatic cancer (E2601). J Clin Oncol 2006, 24(No 18S June 20 Suppl): LBA4040.

19. Rocha Lima C, Green M, Rotche R, Miller W, Jeffrey G, Cisar L, Mortiari R, Millar G, Orlando N, Gruia G, Miller L: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005, 23(15):3509-3516.

20. Stathopoulos G, Aravantinos G, Syrigos K, Kalbakis K, Karvounis N, Papakotoulas P, Boukovinas J, Potamianou A, Polyzos A, Christophilakis C, Georgoulia V: A randomised phase II study of irinotecan gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer. 2005 ASCO Annual Meeting: 2005; Orlando, USA 2005. Abstract no. 4106.

21. Stathopoulos G, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fourati A, Potamianou A, Ziras N, Boukovinas J, Vrachas T, Andoulakis N, Kotsakis A, Samonis G, Georgoulia V: A multicentre phase III trial comparing irinotecan-gemcitabine with gemcitabine monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006, 95(5):587-592.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/8/192/prepub

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime." Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp